SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
Article content
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
Article content
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
Article content
Article content
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
Article content
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
Article content
About SOLVE FSHD
Article content
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Analysts Say AI Could Add $100B+ to Healthcare—But Most Systems Aren't Ready
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – A growing chorus of political and academic voices is calling AI the defining force behind the next evolution in healthcare. Former UK Prime Minister Tony Blair recently warned that failing to embrace AI-driven doctors and nurses could leave entire nations behind, while London Business School professor Nicos Savva echoed the sentiment in Forbes, framing AI as essential to future-ready care. Meanwhile, a new Wolters Kluwer report highlights a troubling disconnect: while interest is surging, most healthcare organizations remain unprepared to deploy GenAI tools at scale. Yet even as institutions scramble to catch up, key breakthroughs are already coming from innovators like Avant Technologies, Inc. (OTCQB: AVAI), Palantir Technologies (NASDAQ: PLTR), Astrana Health, Inc. (NASDAQ: ASTH), Tempus AI, Inc. (NASDAQ: TEM), and SoundHound AI, Inc. (NASDAQ: SOUN). Analysts at McKinsey now estimate that generative AI could generate up to $110 billion in annual value across pharma and medical products alone. Statista projects the broader AI healthcare market will surge from $11 billion today to $188 billion by 2030 — a leap that signals just how quickly the landscape is changing. Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. 'We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally,' said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. 'We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare.' Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July. While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix. In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. 'The cost of a fundus camera has always been a barrier to entry in this market,' said Vargas. 'Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.' Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. 'Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,' said Vargas in a previous statement. 'We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.' As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. Palantir Technologies (NASDAQ: PLTR) has partnered with TeleTracking Technologies to bring real-time AI-driven insights to hospitals and health systems. 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of—where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach,' said Alex Karp, CEO at Palantir. 'Helping to streamline operations allowing for increased focus on providing the best level of care.' By integrating TeleTracking's Operations IQ platform with Palantir's Foundry and AIP tools, the collaboration will enable smarter resource management, predictive forecasting, and near-instant operational decision-making. The combined platform is designed to improve patient flow, reduce staff burden, and drive measurable gains in both care outcomes and financial performance. Astrana Health, Inc. (NASDAQ: ASTH) recently announced a wave of leadership appointments as the company accelerates its national rollout of an AI-driven, value-based care model. The most notable addition is Sherry McBride, a seasoned Medicare Advantage operator who joins as COO to lead integration and execution across Astrana's growing platform. 'We are thrilled to welcome Sherry, along with other recent executive hires and promotions, to the leadership team at a time of immense growth and opportunity for Astrana,' said Brandon Sim, President and CEO of Astrana Health. 'Her deep experience in delegated value-based care will further strengthen our ability to drive consistent, coordinated, high-quality patient outcomes at scale.' Other hires include a new Chief Data and Analytics Officer, Chief Accounting Officer, and Chief People Officer — a signal of Astrana's broader push to deepen capabilities across every operational tier. With a footprint spanning over 12,000 providers and more than a million patients, Astrana is preparing to scale smart, coordinated care on a national level. Tempus AI, Inc. (NASDAQ: TEM) has expanded its generative AI clinical assistant, Tempus One, with direct integration into EHR systems, allowing physicians to query data and streamline workflows in real time. 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' The platform now includes embedded ASCO guidelines, appointment prep tools, and intelligent note-taking — reducing administrative burden and improving decision-making in oncology and beyond. Tempus is also rolling out its Agent Builder tool to select providers, enabling custom GenAI solutions integrated directly into clinical practice. SoundHound AI, Inc. (NASDAQ: SOUN) has partnered with Allina Health to launch 'Alli,' an AI-powered voice agent designed to streamline patient access and reduce administrative bottlenecks. "One of our key goals is to make sure that we're providing a market-leading patient experience," said David Ingham, DO, Chief Information Officer of Allina Health. "Alli is an extension of our team, and we're excited to have her on board to streamline operations, reduce wait times, and deliver a faster, more seamless experience for our patients." Built on the Amelia conversational AI platform, Alli integrates with Allina's EHR system to authenticate callers, manage appointments, and soon handle tasks like refilling medications or answering non-clinical questions. "Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance." Early results show improved call efficiency and faster response times, enabling staff to focus on complex patient needs. CONTACT: cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Globe and Mail
2 hours ago
- Globe and Mail
TerraHash Digital™, a division of AgriFORCE (NASDAQ: AGRI), partners with BlueFlare Energy™ to launch a Power & Compute Initiative, advancing HPC and modular Bitcoin mining infrastructure in Alberta
Vancouver, British Columbia and Grand Prairie, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. ('AgriFORCE' or the 'Company') (NASDAQ: AGRI), an innovation-driven infrastructure and technology company, today announced the launch of a Strategic Power & Compute Initiative in collaboration with BlueFlare Energy ™ Solutions Inc. ('BlueFlare'), a developer of mobile, natural gas-powered generation systems. The partnership signals a major step forward in AgriFORCE's TerraHash Digital ™ strategy to build scalable, high-performance computing (HPC) infrastructure for data-intensive applications, including blockchain networks and modular AI workloads. Modular Power Meets Next-Gen Compute At the heart of the Initiative is a shared vision: transforming stranded or underutilized natural gas resources into resilient, decentralized computing infrastructure. The collaboration will enable the deployment of modular energy and compute systems capable of supporting everything from Bitcoin mining to artificial intelligence, edge computing, and real-time analytics. Under the agreement, AgriFORCE will finance and acquire BlueFlare's proprietary mobile gas-generation units, while BlueFlare will deploy, manage, and operate the end-to-end compute infrastructure. Integrated Technologies for Intelligent Infrastructure The Initiative leverages BlueFlare's full-stack platform for remote site management and real-time optimization: BlueFlare OS ™ – Unified dashboard for fleetwide monitoring of power consumption, uptime, thermal metrics, and hash/computing performance. Performance Optimization Suite – Adaptive control systems for voltage, fan, and clock speed management to extend hardware longevity. Remote Command Layer – Full remote operability with one-click reboot, firmware pushes, and miner resets. Alerting & Predictive Analytics – AI-enabled systems for anomaly detection, maintenance forecasting, and incident prevention. Batch Configuration Tools – Streamlined fleet provisioning for new miners, pools, and compute workloads. Also featured is the BlueFlare Carbon Cube ™, a high-precision environmental monitoring and emissions management platform that supports carbon credit validation and ESG reporting—transforming every site into a measurable sustainability asset. Strategic Growth Path & Infrastructure Rights AgriFORCE has secured a Right of First Refusal (ROFR) on future BlueFlare-sourced sites that align with TerraHash Digital ™ 's expansion criteria. This ensures a consistent and scalable approach to deploying distributed HPC and digital infrastructure across energy-rich regions in Alberta and beyond. 'This Initiative is a leap forward in our mission to make computing infrastructure more scalable, sustainable, and financially efficient,' said Jolie Kahn, CEO of AgriFORCE. 'Together with BlueFlare, we're pioneering a new era of distributed compute—optimized for both environmental impact and performance.' Empowering Rural Innovation Through ESG-Aligned Compute The AgriFORCE–BlueFlare collaboration is designed as a blueprint for regional innovation. By channeling latent energy into data-driven systems, the Initiative promotes rural job creation, grid independence, and carbon offset monetization. ' The Carbon Cube and its supporting technologies represent a breakthrough in transforming stranded or uneconomical energy assets into value-generating infrastructure,' added Dave Jackson, CEO of BlueFlare Energy ™ Solutions Inc. ' Our goal is to not only enable advanced data mining and high-performance computing, but also to generate carbon credits that offset raw energy costs and fuel predictive modeling on the project's frontend. It's a value-added approach that enhances both operational intelligence and environmental accountability. ' About AgriFORCE Growing Systems Ltd. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) is a mission-first company operating at the convergence of agriculture, clean energy, and digital infrastructure. Through its TerraHash Digital ™ division, the company develops and manages high-performance compute environments that support the future of decentralized economies and sustainability. Learn more: About BlueFlare Energy ™ Solutions Inc. Based in Grand Prairie, Alberta, BlueFlare Energy ™ Solutions Inc. is a leader in mobile natural gas-powered generation and decentralized compute technologies. BlueFlare's platforms unlock stranded energy for scalable applications ranging from Bitcoin mining to real-time data processing. Learn more: Follow AgriFORCE on Social Media Follow TerraHash Digital ™ on Social Media Instagram: @Terrahashdigital X (Twitter): @THashDGTL Facebook: TerraHash Digital™ LinkedIn: @TerraHash-Digital TruthSocial: @THashDGTL Forward-Looking Statements This release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Such statements involve known and unknown risks and uncertainties that may cause actual results to differ materially. Readers are encouraged to review AgriFORCE's SEC filings under 'Risk Factors.' The Company disclaims any obligation to update forward-looking statements except as required by law.
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Truck units of Toyota and Daimler reach merger deal, first announced two years ago
TOKYO (AP) — The truck divisions of Japan's Toyota and Daimler of Germany have agreed to merge to form 'a new strong Japanese truck powerhouse' to work together in vehicle development, procurement and production. Details, including the scope and specifics of the collaboration, were still undecided. But Hino Motors and Mitsubishi Fuso Truck and Bus Corp. plan to form a listed holding company by April 2026, the companies said Tuesday. A tentative such deal was announced two years ago. Under the integration, which will be 'on an equal footing,' Daimler Truck and Toyota Motor Corp. will each own 25% of the holding company. The Tokyo-based holding company will own 100% of Mitsubishi Fuso and Hino, and list on the Tokyo Stock Exchange. The chief executive will be Karl Deppen, now CEO of Mitsubishi Fuso, a division of Daimler Truck AG. 'Today is a great day for all our stakeholders. We are shaping the industry by bundling our strengths,' Deppen said. 'With a strong new company, we combine our two trusted brands, our resources, competencies and expertise to even better support our customers in their transportation needs in the future.' The new company, which still needs approval from boards, shareholders and regulatory authorities, will employ more than 40,000 workers. The companies share the common desire to work on future commercial vehicles, strengthening the auto industry in Japan and Asia, and work on ecological innovation, including the use of hydrogen energy, the companies said. Toyota Chief Executive Koji Sato expressed hopes the companies working together will contribute toward building a better future. 'Today's final agreement is not the goal but the starting line. Our four companies, aiming to achieve a sustainable mobility society, will continue to create the future of commercial vehicles together,' he said. Collaboration and the pooling of resources, including money, are becoming widespread in the auto industry, as pressures grow to develop various technology in ecology, autonomous driving, connectivity and safety. And scale can help reduce costs and boost competitiveness. ___ Yuri Kageyama is on Threads:
